StockData

Guardant Health vs Veracyte

GH and VCYT side by side, both in health services. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How GH and VCYT compare

Guardant Health is the larger company, worth 9.9 times as much as Veracyte ($19.2B against $1.9B).

Guardant Health grew revenue faster over the last twelve months (42.7% versus 17.3% for Veracyte).

Veracyte keeps more of each dollar of sales as profit, with a net margin of 20.4% compared with −38.3% at Guardant Health.

Veracyte scores higher on the StockData Score (16 against 10 for Guardant Health), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricGHVCYT
Size and price
Market cap$19.2B$1.9B
Share price$143.28$24.23
Change, 1 year51.8%−38.4%
Change, 5 years34.0%−41.7%
Beta (5Y)1.341.92
Employees2,506755
StockData Score
Total score1016 (better)
Valuation score04 (better)
Growth score4 (better)3
Performance score13 (better)
Health score56 (better)
Dividend score00
Valuation
P/E–17.3×
P/S16.3×3.5× (better)
P/B–1.4×
EV/EBITDA–13.0×
P/FCF–11.7×
FCF yield−1.3%8.5% (better)
Fair value–$36.51
Margin of safety–33.6%
Growth
Revenue growth (TTM)42.7% (better)17.3%
Revenue growth, 5Y average27.9%34.5% (better)
Net income growth (TTM)–335%
EPS growth (TTM)–324%
Profitability
Gross margin65.0%71.7% (better)
Operating margin−39.7%18.8% (better)
Net margin−38.3%20.4% (better)
FCF margin−20.3%29.5% (better)
Return on equity–8.8%
Return on invested capital–10.0%
Financial health
Debt / equity–0.00
Interest coverage−97.6×–
Current ratio4.039.16 (better)
Altman Z-score3.4912.65 (better)
Piotroski F-score67 (better)
Dividends and buybacks
Buyback yield0.00%–
Shareholder yield0.00%0.00%
Ownership
Held by institutions99.8%111%
Held by insiders1.8%1.7%
Insider net buying, 12 months−$173M−$18.6M (better)
Short interest, % of float7.2%12.1%

Go deeper

Other comparisons

For information only, not investment advice. Check the source filings before relying on any figure.